A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT03933943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG: LY3361237
DRUG: Placebo

Sponsor

Eli Lilly and Company